Manuscript ID eji.201847615 entitled "IgG opsonization of viruses suppresses type I and III interferon production by human myeloid antigen-presenting cells via inhibitory signaling by Fc gamma receptor IIa" which you submitted to the European Journal of Immunology has been reviewed. The comments of the referees are included at the bottom of this letter.
A revised version of your manuscript that takes into account the comments of the referees will be reconsidered for publication. Should you disagree with any of the referees' concerns, you should address this in your point-by-point response and provide solid scientific reasons for why you will not make the requested changes.
You should also pay close attention to the editorial comments included below. **In particular, please edit your figure legends to follow Journal standards as outlined in the editorial comments. For all data, including the new data generated for the revision of the manuscript, please report in the Figure legends the number of independent experiments and number of samples per experiment (or experimental replicates). For flow cytometry data please show the full gating strategy, including the percentage of cells in the region or gate or event count. In the histograms/dot plots shown please report which fluorochromes were used and the scaling in the axis (log/lin). Failure to do this will result in delays in the re-review process.** Please note that submitting a revision of your manuscript does not guarantee eventual acceptance, and that your revision will be re-reviewed by the referees before a decision is rendered.
If the revision of the paper is expected to take more than three months, please inform the editorial office.
Revisions taking longer than six months may be assessed by new referees to ensure the relevance and timeliness of the data.
Once again, thank you for submitting your manuscript to European Journal of Immunology and we look forward to receiving your revision. Further along these lines, the vast majority of the data has not been generated with virus ICs. To maintain the title of the paper it would be critical to show that FcRIIa blockade enhances type I IFN production in the context of opsonized virus instead of just using TLR ligands.
Furthermore, the authors state that human DCs behave different than mouse DCs. This statement (and the shown data) is problematic as human DCs and mouse DCs were generated with different protocols (blood versus bone marrow, IL4 present in human DC cultures versus absent in mouse DC cultures, etc.).
To make this statement the authors should generate DCs under the same conditions. Moreover, DCs exist in many subsets, which may or may not react in the way as shown for blood derived DCs. This should be discussed in much greater detail.
First Revision -authors' response -17-Jul-2018
We thank the reviewers for their comments and suggestions and are glad to hear that they consider this work of potential interest for publication in the European Journal of Immunology. Below we have made a point-by-point response to the reviewer's comments.
Reviewer 1
The The reviewer is right that it should be verified that the infection rate is similar between virus exposure with and without antibodies. We now show this in Figure 1B (previously, this was shown as supplementary data, but we realize that this important control should be included as a main figure).
TLR9 is thought to be primarily expressed by plasmacytoid DCs. How do the authors envision that CpG induces type I and III interferon in myeloid DCs, which they then report to be attenuated by immune complexes? Do they authors detect expression of TLR9 by human monocyte-derived DCs?
The reviewer certainly raises a good point here. We have stimulated monocyte-derived DCs (moDCs) with CpG since it has previously been described that monocyte-derived DCs express TLR9 and respond to 
How does FcgammaRIIa inhibit type I and III interferon production? Some information how an activating
Fcgamma receptor can achieve this, should be provided.
As requested by the reviewer, we have further looked into the mechanism of FcγRIIa-mediated type I IFN suppression. Since we identified that FcγRIIa inhibits type I IFN production at the level of gene transcription, we have assessed the expression of the main transcription factors of type I IFN, i.e. IRF1, IRF3, and IRF7. Importantly, while we did not observe any difference in IRF3 and IRF7 expression, we identified that FcγRIIa co-stimulation down-regulates the expression of IRF1 ( Figure 6D ). As requested, we have now added statistical evaluation for several key experiments. These are depicted in Figures 1D, 1F , 2B, and Supplementary Figure 1A .
Reviewer 2

While the authors show that adding IgG 0.5 hrs after virus does not alter virus mRNA in the cell they do not show proof that a virus IC is generated under these conditions. The could elute virus IgG complexes from the cell surface to proof this.
The reviewer is right that it is important to verify that the antibodies indeed recognize and bind to the viruses. Therefore, we have assessed binding of antibodies to both influenza and RSV using an ELISA setup ( Figure 1A ), which confirmed IgG binding to the viruses (previously, this was shown as supplementary data, but we agree that this control should be included as a main figure) . Taken together, we believe that the additional experimental data and textual adjustments have greatly strengthened the manuscript. We thank the reviewers for their comments and suggestions and look forward to their reply. 
Most forward, I have a major concern with the results in Figures 2-6 as the authors never use immune complexes but instead immobilize IgG on plastic. This by no means allows inferring how
